Multicenter, double-blind, randomized, placebo-controlled study of levetiracetam as add-on therapy in Japanese patients with uncontrolled partial seizures

Journal of the Japan Epilepsy Society

Volumn 28, Issue 1, 2010, Pages 3-16

  Yagi, Kazuichi ^a   Kameyama, Shigeki ^b   Kaneko, Sunao ^c   Murasaki, Mitsukuni ^d   Yamauchi, Toshio ^e  

^a SHIZUOKA INSTITUTE OF EPILEPSY AND NEUROLOGICAL DISORDERS   (Japan)

^b NISHI NIIGATA CHUO NATIONAL HOSPITAL   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

^d Institute of CNS Pharmacology

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Add on therapy; Antiepileptic drugs; Epilepsy; Levetiracetam; Partial seizures

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; PHENOBARBITAL; PHENYTOIN; PLACEBO; VALPROIC ACID;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOCAL EPILEPSY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SOMNOLENCE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77955618392     PISSN: 09120890     EISSN: 13475509     Source Type: Journal    
DOI: 10.3805/jjes.28.3     Document Type: Article

References (27)

1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-319.
2. http://square.umin.ac.jp/jes/pdf/SEIJIN.pdf
3. Gower AJ, Noyer M, Verloes R, et al. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. European Journal of Pharmacology 1992; 222: 193-203.
4. Klitgaard H, Matagne A, Gobert J, Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. European Journal of Pharmacology 1998; 353:191-206. (Pubitemid 28352266)
5. Löscher W, Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. European Journal of Pharmacology 1993; 232: 147-158. (Pubitemid 23080189)
6. Gower AJ, Hirsch E, Boehrer A, et al. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Research 1995; 22: 207-213.
7. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 9861-9866.
8. Cereghino JJ, Biton V, Abou-Khalil B, et al, the United States Levetiracetam Study Group. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-242.
9. Ben-Menachem E, Falter U, the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41:1276-1283.
10. Shorvon SD, Löwenthal A, Janz D, et al, the European Levetiracetam Study Group. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41: 1179-1186.
11. Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, et al, the N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006; 66: 1654-1660.
12. Piña-Garza JE, Nordli DR Jr, Rating D, Yang H, Schiemann-Delgado J, Duncan B, the Levetiracetam N01009 Study Group. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia 2009; 50 (5): 1141-1149.
13. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ, Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402-408.
14. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J, N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008; 70: 607-616.
15. Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U, Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007; 69 (18): 1751-1760.
16. Tsai JJ, Yen DJ, Hsih MS, Chen SS, Hiersemenzel R, Edrich P, et al. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia 2006; 47 (1): 72-81.
17. Wu XY, Hong Z, Wu X, Wu LW, Wang XF, Zhou D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Epilepsia 2008; 50 (3): 398-405.
18. Heo K, Lee BI, Yi SD, Huh K, Kim JM, Lee SA, et al. Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients. Seizure 2007; 16 (5): 402-409.
19. Otoul C, Arrigo C, van Rijckevorsel K, French JA. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clinical Neuropharmacology 2005; 28: 72-78. (Pubitemid 40471880)
20. Brodie JM. Medical therapy of epilepsy: When to initiate treatment and when to combine? J Neurol 2005; 252: 125-130.
21. French J, di Nicola S, Arrigo C. Fast and sustained efficacy of levetiracetam during titration and the first 3 months of treatment in refractory epilepsy. Epilepsia 2005; 46 (8): 1304-1307. (Pubitemid 41647772)
22. Panayiotopoulos CP. A clinical guide to epileptic syndromes and their treatment. 2nd edition. London: Springer, 2007: 155-184.
23. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacology and Therapeutics 2000; 85: 77-85.
24. 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. European Journal of Clinical Pharmacology 2003; 59: 621-630.
25. Pigeolet E, Jacqmin P, Sargentini-Maier M-L, Stockis A. Population pharmacokinetics of levetiracetam in Japanese and Western Adults. Clinical Pharmacokinetics 2007; 46 (6): 503-512.
26. Stodieck S, Steinhoff BJ, Kolmsee S, Van Rijckevorsel K. Effect of levetiracetam in patients with epilepsy and interictal epileptiform discharges. Seizure 2001; 10: 583-587. (Pubitemid 34083170)
27. Carpenter D, Karceski S, Morrell MJ. Treatment of Epilepsy in Adults: expert Opinion, 2005. Epilepsy Behav 2005; 7: S 1-64.